Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.7750
0.046.11%
At close: -
$0.7803
0.005300.68%
After Hours: 7:55 PM EDT
Comments
Loading...
Immunic Analyst Ratings and Price Targets | NASDAQ:IMUX | Benzinga
Immunic Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Immunic Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
D. Boral Capital
B. Riley Securities
HC Wainwright & Co.
EF Hutton
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for Immunic
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/29/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert45% | $17 → $10 | Maintains | Buy | Get Alert |
| 05/23/2025 | Buy Now | — | B. Riley Securities | William Woods26% | $6 → $5 | Reiterates | Buy → Buy | Get Alert |
| 05/01/2025 | Buy Now | — | HC Wainwright & Co. | Matthew Caufield38% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 04/30/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert45% | $17 → $17 | Maintains | Buy | Get Alert |
| 04/16/2025 | Buy Now | — | B. Riley Securities | William Woods26% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 04/15/2025 | Buy Now | — | HC Wainwright & Co. | Matthew Caufield38% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert45% | $17 → $17 | Maintains | Buy | Get Alert |
| 04/01/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert45% | $17 → $17 | Maintains | Buy | Get Alert |
| 03/25/2025 | Buy Now | — | William Blair | Myles Minter38% | — | Initiates | → Outperform | Get Alert |
| 02/26/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert45% | $17 → $17 | Maintains | Buy | Get Alert |
| 02/21/2025 | Buy Now | — | HC Wainwright & Co. | Matthew Caufield38% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 02/20/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert45% | $17 → $17 | Maintains | Buy | Get Alert |
| 01/07/2025 | Buy Now | — | D. Boral Capital | Jason Kolbert45% | $17 → $17 | Maintains | Buy | Get Alert |
| 11/25/2024 | Buy Now | — | HC Wainwright & Co. | Matthew Caufield38% | → $10 | Initiates | → Buy | Get Alert |
| 11/07/2024 | Buy Now | — | EF Hutton | Jason Kolbert45% | $17 → $17 | Maintains | Buy | Get Alert |
| 10/22/2024 | Buy Now | — | EF Hutton | Jason Kolbert45% | $17 → $17 | Maintains | Buy | Get Alert |
| 09/18/2024 | Buy Now | — | EF Hutton | Jason Kolbert45% | $17 → $17 | Maintains | Buy | Get Alert |
| 09/16/2024 | Buy Now | — | EF Hutton | Jason Kolbert45% | → $17 | Initiates | → Buy | Get Alert |
| 09/09/2024 | Buy Now | — | Leerink Partners | Faisal Khurshid37% | → $5 | Assumes | → Outperform | Get Alert |
| 08/27/2024 | Buy Now | — | B. Riley Securities | William Woods26% | → $6 | Initiates | → Buy | Get Alert |
| 07/16/2024 | Buy Now | — | Piper Sandler | Yasmeen Rahimi57% | $28 → $28 | Reiterates | Overweight → Overweight | Get Alert |
| 04/05/2024 | Buy Now | — | Brookline Capital | Tyler Bussian22% | → $10 | Initiates | → Buy | Get Alert |
| 10/10/2023 | Buy Now | — | Wedbush | Andreas Argyrides71% | $5 → $7 | Maintains | Outperform | Get Alert |
| 07/27/2023 | Buy Now | — | Wedbush | Andreas Argyrides71% | → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 01/31/2023 | Buy Now | — | Wedbush | Andreas Argyrides71% | → $5 | Assumes | → Outperform | Get Alert |
| 10/21/2022 | Buy Now | — | SVB Leerink | Thomas Smith33% | $9 → $5 | Downgrade | Outperform → Market Perform | Get Alert |
| 09/19/2022 | Buy Now | — | HC Wainwright & Co. | Gobind Singh20% | → $26 | Assumes | → Buy | Get Alert |
| 08/08/2022 | Buy Now | — | Aegis Capital | Nathan Weinstein31% | $40 → $35 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Immunic (IMUX) stock?
The latest price target for Immunic (NASDAQ:IMUX) was reported by D. Boral Capital on May 29, 2025. The analyst firm set a price target for $10.00 expecting IMUX to rise to within 12 months (a possible 1181.56% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Immunic (IMUX)?
The latest analyst rating for Immunic (NASDAQ:IMUX) was provided by D. Boral Capital, and Immunic maintained their buy rating.
When was the last upgrade for Immunic (IMUX)?
There is no last upgrade for Immunic
When was the last downgrade for Immunic (IMUX)?
The last downgrade for Immunic Inc happened on October 21, 2022 when SVB Leerink changed their price target from $9 to $5 for Immunic Inc.
When is the next analyst rating going to be posted or updated for Immunic (IMUX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunic was filed on May 29, 2025 so you should expect the next rating to be made available sometime around May 29, 2026.
Is the Analyst Rating Immunic (IMUX) correct?
While ratings are subjective and will change, the latest Immunic (IMUX) rating was a maintained with a price target of $17.00 to $10.00. The current price Immunic (IMUX) is trading at is $0.78, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
